Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast
Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1 therapies Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) have become staples in earlier treatment lines, and Keytruda is now poised to become the standard of care in the first-line setting in combination with the antibody-drug conjugate (ADC), Padcev (Seagen / Pfizer / Astellas), for all patients regardless of platinum sensitivity. The PD-L1 inhibitor, Bavencio (Merck KGaA / Pfizer), approved as first-line maintenance treatment, highlights the expanded use of immune checkpoint inhibitors in all lines of therapy. In addition, the approvals of ADCs, Padcev and Trodelvy (Gilead), have diversified the treatment paradigm in later treatment lines. In 2022, Adstiladrin (Ferring Pharmaceuticals) became the first gene therapy to treat high-risk non-muscle invasive bladder cancer in the United States, and several new therapies with novel combinations and MOAs, anticipated to be approved by 2033, will only intensify the competition in this market.
Question answered
- What are the sizes of the clinically and commercially relevant drug-treatable populations in this market? and how will drug-treatment rates change over time?
- How is bladder cancer and UTUC currently treated, and how do their treatment options differ? What are the key advantages and disadvantages of existing drugs and impact of recent approvals?
- Which of the emerging therapies are viewed as most promising, and what sales / uptake could they secure in this market?
- What are the key market drivers and constraints, and how will the market evolve over the 10-year forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Bladder Cancer and Upper Tract Urothelial Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market share of drug classes for bladder cancer and UTUC: 2022
- Market share of drug classes for bladder cancer and UTUC: 2032
- Drug-treatable population share and major-market sales share in bladder cancer and UTUC: 2022
- Drug-treatable population share and major-market sales share in bladder cancer and UTUC: 2032
- Population positioning of therapies in bladder cancer and UTUC: United States
- Population positioning of therapies in bladder cancer and UTUC: Europe
- Population positioning of therapies in bladder cancer and UTUC: Japan
- Bladder cancer and UTUC SWOT analysis
- Market drivers and constraints
- What factors are driving the market for bladder cancer and UTUC?
- What factors are constraining the market for bladder cancer and UTUC?
- Major market sales of key therapies (excluding immune checkpoint inhibitors) in the bladder cancer and UTUC market: 2022-2032
- Major market sales of immune checkpoint inhibitors in the bladder cancer and UTUC market: 2022-2032
- Segment-specific trends
- Key findings
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Key findings
- Epidemiology populations
- Diagnosed incident cases
- Stage distribution of bladder cancer and upper tract urothelial carcinoma
- Locally recurrent incident cases of bladder cancer and upper tract urothelial carcinoma
- Intravesical recurrent incident cases of upper tract urothelial carcinoma
- Metastatic recurrent incident cases of bladder cancer and upper tract urothelial carcinoma
- Drug-treatable populations
- Drug-treated populations
- Key findings
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for bladder cancer and UTUC
- Current treatments used for bladder cancer and UTUC
- Market events impacting the use of key current therapies in bladder cancer and UTUC
- Immune checkpoint inhibitors
- Antibody-drug conjugates
- FGFR inhibitors
- Chemotherapy
- Viral-vector therapies
- Medical practice
- Non-muscle-invasive bladder cancer and UTUC
- Localized and resectable locally advanced bladder cancer and UTUC
- First-line unresectable locally advanced or metastatic bladder cancer and UTUC
- Second- and third-line metastatic bladder cancer and UTUC
- Patient characteristics influencing drug selection in bladder cancer and UTUC
- Region-specific treatment practices
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Liseth Parra, Ph.D., is an analyst on the Oncology team at Clarivate. She has extensive background in oncology research and market analysis. She completed a postdoctoral fellowship in oncology at Brigham and Women’s Hospital in Boston, along with commercial work as an oncology research analyst for Kantar Health and as an independent consultant. She also worked as a research fellow at the Novartis Institutes for BioMedical Research in Basel, Switzerland, and at the Fritz Lipmann Institute in Jena, Germany. Dr. Parra completed her doctorate in neurosciences at the University of California in San Diego.
Marcos Fernández Alfara, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Fernández has extensive experience in oncology, with a focus on novel immunotherapies for solid tumors. As part of his doctorate, he developed new strategies to boost immune responses against cancer cells. He obtained his master of science degree in cancer and stem cells from Utrecht University and his doctorate in biomedicine from the Institute for Research in Biomedicine at Barcelona University.